Knowledge-based SBDD & LBDD
The most widely-used hit identification strategy for fast-follower approaches.
Our medicinal and computational chemists exploit published and proprietary information on the protein structure and known ligands to derive innovative chemical start points.
This cost-efficient strategy maximizes recent technological advances in computational chemistry and showcases the enhanced performance enabled by AI methodology.
Our CADD team designs bespoke in silico workflows to identify virtual hits from large commercial collections. In vitro confirmation and ADMET profiling provide high-quality hits in a matter of weeks from start to finish.
A lean strategy to identify chemical start points for all biological targets including those that are difficult-to-drug.
Our in vitro biology labs are equipped with state-of-the-art biophysical instrumentation enabling the rapid screening of our proprietary Biophysical Fragment collection.
Medium throughput screening
A proven strategy for novel biological targets.
We combine our liquid handling technology and biophysical/biochemical screening expertise to screen up to 25,000 compounds from commercial and proprietary compound collections.